Ann: December 2017 Appendix 4C - Quarterly, page-2

7mil (approx) in funds available R&D tax refund inclusive.
SP between 6.5 to 7cents, MC 14mil (approx).
With current pipeline, it’s a screaming bargain entry point..., yet unloved.
Looking forward to breast cancer full analysis (Q1).
Must be of concern not only to long term holders as to management alike on shareholders value appreciation strategy and results.
Happy to hold and still accumulating for now, am aware of biotech patience requirements.
Yes., also aware ‘ once bitten twice shy’ withdrawn mentally of holders no longer.
Would like to see new investors/ holders this year and hoping for a similar sentiment by management.
That is, proactive beyond just clinical results onus.
Not bitter just time to move on from 2017.
Others? Thoughts?